000109706 001__ 109706
000109706 005__ 20230519145555.0
000109706 0247_ $$2doi$$a10.3390/pharmaceutics13121988
000109706 0248_ $$2sideral$$a126772
000109706 037__ $$aART-2021-126772
000109706 041__ $$aeng
000109706 100__ $$0(orcid)0000-0002-1407-5922$$aArauzo, B.$$uUniversidad de Zaragoza
000109706 245__ $$aExcipient-free inhalable microparticles of Azithromycin produced by electrospray: A novel approach to direct pulmonary delivery of antibiotics
000109706 260__ $$c2021
000109706 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109706 5203_ $$aInhalation therapy offers several advantages in respiratory disease treatment. Azithromycin is a macrolide antibiotic with poor solubility and bioavailability but with a high potential to be used to fight lung infections. The main objective of this study was to generate a new inhalable dry powder azithromycin formulation. To this end, an electrospray was used, yielding a particle size around 2.5 µm, which is considered suitable to achieve total deposition in the respiratory system. The physicochemical properties and morphology of the obtained microparticles were analysed with a battery of characterization techniques. In vitro deposition assays were evaluated after aerosolization of the powder at constant flow rate (100 L/min) and the consideration of the simulation of two different realistic breathing profiles (healthy and chronic obstructive pulmonary disease (COPD) patients) into a next generation impactor (NGI). The formulation was effective in vitro against two types of bacteria, Staphylococcus aureus and Pseudomonas aeruginosa. Finally, the particles were biocompatible, as evidenced by tests on the alveolar cell line (A549) and bronchial cell line (Calu-3). © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000109706 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109706 590__ $$a6.525$$b2021
000109706 592__ $$a0.922$$b2021
000109706 594__ $$a6.0$$b2021
000109706 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 279 = 0.14$$c2021$$dQ1$$eT1
000109706 593__ $$aPharmaceutical Science$$c2021$$dQ1
000109706 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109706 700__ $$aLopez-Mendez, T.B.
000109706 700__ $$0(orcid)0000-0002-2436-1041$$aLobera, M.P.$$uUniversidad de Zaragoza
000109706 700__ $$0(orcid)0000-0002-1603-7305$$aCalzada-Funes, J.$$uUniversidad de Zaragoza
000109706 700__ $$aPedraz, J.L.
000109706 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaria, J.$$uUniversidad de Zaragoza
000109706 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000109706 773__ $$g13, 12 (2021), 1988 [17 pp]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000109706 8564_ $$s11148143$$uhttps://zaguan.unizar.es/record/109706/files/texto_completo.pdf$$yVersión publicada
000109706 8564_ $$s2763176$$uhttps://zaguan.unizar.es/record/109706/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109706 909CO $$ooai:zaguan.unizar.es:109706$$particulos$$pdriver
000109706 951__ $$a2023-05-18-15:54:28
000109706 980__ $$aARTICLE